Dystrophic Epidermolysis Bullosa Treatment Market: Introduction
According to the report, the global dystrophic epidermolysis bullosa treatment market was valued over US$ 412 Mn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030. Dystrophic epidermolysis bullosa (DEB) is the second most common form of epidermolysis bullosa. The prevalence of DEB varies from 1 per 49,000 inhabitants in Scotland to 1 per 420,168 in the U.S. According to the U.S. National Library of Medicine, the prevalence of recessive and dominant dystrophic epidermolysis bullosa is estimated at 3.3 per million people.
North America dominated the global dystrophic epidermolysis bullosa treatment market in 2019 and the trend is anticipated to continue during the forecast period. The rise in population suffering from various diseases in North America has increased the number of patients visiting hospitals. Hence, the consumption of dystrophic epidermolysis bullosa treatment products is expected to increase during the forecast period.
Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=79063
North America’s large share of the global dystrophic epidermolysis bullosa treatment market can be attributed to high cost of biologic drugs compared to other regions. It is a key target region for all players in the global dystrophic epidermolysis bullosa treatment market. Asia Pacific is likely to be a highly lucrative market for dystrophic epidermolysis bullosa treatment from 2020 to 2030. The market in the region is projected to expand at a high CAGR during the forecast period.
Antibiotics to Dominate Global Market
In terms of treatment type, the global dystrophic epidermolysis bullosa treatment market has been classified into antibiotics, corticosteroids, opioid analgesics, anticonvulsant, and others. The antibiotics segment dominated the global dystrophic epidermolysis bullosa treatment market in 2019 and the trend is projected to continue during the forecast period.
A large number of antibiotics is in late phases of clinical pipeline trials and are likely to be commercialized between 2019 and 2025. Anticipated launch and adoption of antibiotics to address unmet medical needs in dystrophic epidermolysis bullosa treatment are expected to propel the segment during the forecast period.
Request for Custom Research – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=79063
Dominant Dystrophic Epidermolysis Bullosa (DDEB) to be Highly Lucrative
Based on service provider, the global dystrophic epidermolysis bullosa treatment market has been bifurcated into dominant dystrophic epidermolysis bullosa (DDEB) and recessive dystrophic epidermolysis bullosa (RDEB). The dominant dystrophic epidermolysis bullosa (DDEB) segment dominated the global dystrophic epidermolysis bullosa treatment market due to large number of patients suffering from dominant dystrophic epidermolysis bullosa. According to the National EB Registry, the overall prevalence of EB is 11.07 per one million live births. The prevalence of DDEB and RDEB is 1.49 and 1.35 per one million live births, respectively.
Buy Dystrophic Epidermolysis Bullosa Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=79063<ype=S
Key players in the global dystrophic epidermolysis bullosa treatment market include Krystal Biotech, Castle Creek Biosciences, Inc., Abeona Therapeutics, Inc., Amryt Pharma plc, Wings Therapeutics, Phoenix Tissue Repair, InMed Pharmaceuticals, Inc., RegeneRx, and Holostem Terapie Avanzate S.r.l.
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information, we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Mr. Rohit Bhisey
Transparency Market Research
USA – Canada Toll Free: 866-552-3453